AI주식인사이트AI Stock Insight
C

삼양바이오팜

0120G0KOSPI

52.3 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40
News Sentiment18.3 / 25
Momentum8.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 14.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samyang Biopharm operates in three main business segments: medical devices, pharmaceuticals, and new drug development. Key products include biodegradable surgical sutures and hemostatic agents in the medical device sector, and anticancer drugs for solid and blood cancers in the pharmaceutical sector. The company is developing gene therapy platforms (SENS) for new drug research, with medical devices contributing 62.5% of total revenue.

Number of Employees

407people

Average Salary

79.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
166.90Industry Average 15.000.0Point

11.1x industry avg (risky)

PBR
1.59Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
—Industry Average 8.003.5Point
Debt Ratio
1.29Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
2.0 / 4

Detailed News Sentiment

17 totalPositive 11Neutral 3Negative 3Average Sentiment Score 73.2

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 50,200Won52-week high 142,70052-week low 30,200
1-month return5.0Point

1m +14.22% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 4Negative 1
  • Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-31
  • Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral최대주주등소유주식변동신고서2026-08-10
  • Neutral주식등의대량보유상황보고서(일반)2026-08-10